David Calvet Canut on Takeda’s HyHub: A Shift Toward Patient-Centered Biologics
David Calvet Canut, Director TFE at UNIR, shared on LinkedIn:
“Takeda’s new HyHub™ system for HYQVIA® represents a significant advancement in patient-centered plasma-derived therapies. By simplifying subcutaneous immunoglobulin infusions, it enhances convenience and treatment adherence—areas where even small innovations can lead to meaningful improvements.
For biotech companies, this serves as a reminder that value creation now extends beyond just the molecule itself. Integration of devices, enhancement of patient experience, and home-based delivery are becoming crucial factors for competitive differentiation and securing reimbursement.
The field of plasma-derived therapies continues to evolve, and these hybrid therapy-plus-device models have the potential to redefine how we design, finance, and scale future biologics.”
Read full paper here.
Stay informed with Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology